Gland Pharma soars on getting EIR from USFDA for Visakhapatnam facility
Gland Pharma is currently trading at Rs. 1780.00, up by 36.20 points or 2.08% from its previous closing of Rs. 1743.80 on the BSE.
The scrip opened at Rs. 1587.55 and has touched a high and low of Rs. 1800.00 and Rs. 1587.55 respectively. So far 3074 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2220.95 on 06-Aug-2024 and a 52 week low of Rs. 1200.00 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 1800.00 and Rs. 1587.55 respectively. The current market cap of the company is Rs. 29303.58 crore.
The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 40.17% and 7.99% respectively.
Gland Pharma has received Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) indicating closure of Pre-approval inspection (PAI) for Sterile APIs at JNPC, Visakhapatnam facility. The said inspection was conducted between February 19, 2025 and February 25, 2025.
Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.
